Stage IV-N: A favorable subset of children with metastatic neuroblastoma
β Scribed by Rosen, Eliot M. ;Cassady, J. Robert ;Frantz, Christopher N. ;Kretschmar, Cynthia S. ;Levey, Raphael ;Sallen, Stephen E.
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 436 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Among children over 1 year of age with are long-term disease-free survivors, com-Evans Stage IV neuroblastoma, there appears pared with none of 40 patients with extranoto be a small group with a relatively favorable dal metastatic disease (p < 0.0002). Patients prognosis. These patients have extensive with only lymph node metastases (Stage "IV- lymph node metastases (cervical/axillary/tho-N") may have a biologically more favorable racic/abdominal/pelvic), but no extranodal tumor that is curable with conventional, inmetastases. Three of six such patients (50%) tensive multimodality therapy.
π SIMILAR VOLUMES
The purpose of this study was to evaluate the effect of the sequential addition of doxorubicin and cyclophosphamide to the combination of vincristine and actinomycin D o n the relapse-free survival of children with stage IV/favorable histology Wilms tumor. We reviewed the clinical courses of all ran
Background. Current treatment of stage III favorable histology (FH) Wilms tumor is surgery, radiotherapy to residual disease, and ''triple'' chemotherapy (vincristine, dactinomycin, and doxorubicin) for 12 months. This study tests the hypothesis that some stage III patients, especially very young ch
## Abstract bclβ6, CD10 and CD38 are useful markers for identifying 2 molecularly and prognostically distinct profiles of diffuse large Bβcell lymphomas (LCLs), defined as germinalβcenter Bβlike and activated Bβlike. We investigated the prognostic role of bclβ6, CD10 and CD38 immunoreactivity in 10